Literature DB >> 25295651

The potential for misuse and abuse of medications in ADHD: a review.

David B Clemow1, Daniel J Walker.   

Abstract

This article reviews the literature concerning attention-deficit/hyperactivity disorder (ADHD) medication misuse, abuse, dependence, diversion, and malingering. The review covers nonmedical use (NMU) of both stimulant (methylphenidate and amphetamine) and nonstimulant (α-adrenergic agonists and atomoxetine) prescription medications, and provides a discussion on the relevance for ADHD treatment today. The neural basis for ADHD medication mechanisms of action (increased norepinephrine and dopamine signaling) and their neurobiochemical relationship to the abuse potential is explored. Regionally-specific, stimulant-induced elevations in brain dopamine appear to be integral to both efficacy in ADHD and potential for abuse. In addition to the prevalence of misuse and diversion, additional topics discussed include the potential safety concerns associated with NMU of prescription ADHD medications and the cost to payers of prescription drug diversion (eg, increased emergency department visits associated with misuse). The evidence describing the difficulty in detecting malingering for the purpose of illicit access to ADHD medications for subsequent misuse or diversion is also summarized. Moreover, the effect of ADHD medications in patients with comorbid substance use disorder and the controversial potential linkage of stimulant prescription use with subsequent substance use disorder are explored. Overall, the data suggest that ADHD medication misuse and diversion are common health care problems for stimulant medications, with the prevalence believed to be approximately 5% to 10% of high school students and 5% to 35% of college students, depending on the study. Stimulant effectiveness and speed of action are deemed desirable to enhance attention and focus performance for activities like studying, but stimulants are also misused recreationally. Conversely, the data suggest a lack of abuse potential and lack of actual medication misuse for the nonstimulant medications. Although they can be efficacious for the treatment of ADHD, the nonstimulants lack a mechanism of action linked to the abuse potential and they lack the desirable effects (speed of action, stimulant feel) that make stimulants susceptible to NMU. In light of these findings, the data suggest a need for close screening and therapeutic monitoring of ADHD medication use. In addition, nonstimulants might be an appropriate alternative for patients with concern about abuse and physicians concerned with general misuse and diversion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25295651     DOI: 10.3810/pgm.2014.09.2801

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  34 in total

1.  A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder.

Authors:  Jon E Grant; Stephanie Valle; Elizabeth Cavic; Sarah A Redden; Samuel R Chamberlain
Journal:  Int J Eat Disord       Date:  2019-04-02       Impact factor: 4.861

2.  Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.

Authors:  Nicholas King; Samuel Floren; Natasha Kharas; Ming Thomas; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2019-06-19       Impact factor: 3.533

Review 3.  Consequences of adolescent use of alcohol and other drugs: Studies using rodent models.

Authors:  Linda Patia Spear
Journal:  Neurosci Biobehav Rev       Date:  2016-07-30       Impact factor: 8.989

Review 4.  TAAR Agonists.

Authors:  Zhengrong Xu; Qian Li
Journal:  Cell Mol Neurobiol       Date:  2019-12-17       Impact factor: 5.046

5.  Stimulant Diversion Risk Among College Students Treated for ADHD: Primary Care Provider Prevention Training.

Authors:  Brooke S G Molina; Heidi L Kipp; Heather M Joseph; Stacey A Engster; Seth C Harty; Montaya Dawkins; Rachel A Lindstrom; Daniel J Bauer; Srihari S Bangalore
Journal:  Acad Pediatr       Date:  2019-06-08       Impact factor: 3.107

Review 6.  Redesigning Care for OSA.

Authors:  Lucas M Donovan; Aditi Shah; Ching Li Chai-Coetzer; Ferran Barbé; Najib T Ayas; Vishesh K Kapur
Journal:  Chest       Date:  2019-10-19       Impact factor: 9.410

7.  Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.

Authors:  Pernille Warrer; Per Hove Thomsen; Søren Dalsgaard; Ebba Holme Hansen; Lise Aagaard; Helle Wallach Kildemoes; Henrik Berg Rasmussen
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-18       Impact factor: 2.576

8.  Acute and chronic methylphenidate administration in intact and VTA-specific and nonspecific lesioned rats.

Authors:  Stephanie A Ihezie; Ming M Thomas; Nachum Dafny
Journal:  J Neural Transm (Vienna)       Date:  2019-01-08       Impact factor: 3.575

Review 9.  Transcranial Magnetic Stimulation in Treatment of Adolescent Attention Deficit/Hyperactivity Disorder: A Narrative Review of Literature.

Authors:  Aksha M Memon
Journal:  Innov Clin Neurosci       Date:  2021-01-01

10.  Effects of benztropine analogs on delay discounting in rats.

Authors:  Paul L Soto; Takato Hiranita
Journal:  Psychopharmacology (Berl)       Date:  2020-09-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.